Catalog No.A2017 Synonyms: PDR001 Non-humanized mouse model applicable
For research use only. Not for use in humans.
Spartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1.
Choose Selective PD-1/PD-L1 Inhibitors
|Description||Spartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1.|
|In vivo||In phase 1/2 studies, PDR001 has a manageable safety profile and preliminary antitumor activity in advanced solid tumors.|
|Formulation||PBS buffer, pH 7.2|
|Storage||Store at -80°C and avoid freeze-thaw cycles.|
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03081494||Recruiting||Metastatic Colorectal Cancer||Novartis Pharmaceuticals|Novartis||June 9 2017||Phase 1|
|NCT03172936||Recruiting||Solid Tumors and Lymphomas||Novartis Pharmaceuticals|Novartis||September 8 2017||Phase 1|
|NCT03066648||Recruiting||Leukemia|Leukemia Myeloid|Leukemia Myeloid Acute|Myelodysplastic Syndromes|Preleukemia|Bone Marrow Diseases|Hematologic Diseases||Novartis Pharmaceuticals|Novartis||July 6 2017||Phase 1|
|NCT03301896||Recruiting||Solid Tumors||Novartis Pharmaceuticals|Novartis||January 31 2018||Phase 1|
|NCT03609424||Not yet recruiting||Gastrointestinal Stromal Tumors||Asan Medical Center|Novartis||September 30 2018||Phase 1|Phase 2|
|NCT02807844||Recruiting||Triple Negative Breast Cancer|Pancreatic Carcinoma|Melanoma|Endometrial Carcinoma||Novartis Pharmaceuticals|Novartis||June 29 2016||Phase 1|Phase 2|
If you have any other enquiries, please leave a message.